[治疗性使用大麻素的要求:如何支持患者?]
Déborah Lidsky-Haziza1, Thierry Favrod-Coune1, Barbara Broers1
1Unité des dépendances, Service de médecine de premier recours, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue medicale suisse
|June 5, 2024
概括
当其他治疗方法失败时,医用大麻可以缓解严重症状. 改善瑞士患者获取医疗服务需要解决处方知识缺口和成本障碍,以提高生活质量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 医学治疗学 医学治疗学
背景情况:
- 大麻用于缓解标准治疗不耐药的症状,通常作为最后的手段.
- 尽管瑞士患者的兴趣和政治支持越来越多,但实际获得医用大麻素仍然具有挑战性.
- 障碍包括有限的强大的医疗指示,高昂的成本 (通常不被退还),以及医生对处方知识的不足.
研究的目的:
- 评估挑战,并提出在瑞士医疗大麻素获取的务实方法.
- 倡导以患者为中心的护理,以医用大麻治疗疾病.
主要方法:
- 对当前进入障碍物的定性分析.
- 审查关于大麻素有效性和风险的现有文献.
- 关于患者自主权和接触权的伦理考虑.
主要成果:
- 大麻的医疗用途主要是用于严重的,耐治疗的症状和改善生活质量.
- 缺乏明确的医疗指导方针,财政负担和医生教育赤字阻碍了获取医疗服务.
- 大麻素对医疗应用具有较低的风险.
结论:
- 建议采取务实的方法,尊重患者获得医用大麻素的权利.
- 赋予患者评估治疗效果的权力可以增强治疗关系和患者参与疾病管理.
- 解决系统性障碍对于公平获得基于大麻的疗法至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
224
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
224
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
183
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
183
Analgesia and Pain Management
579
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
579
Opioid Analgesics: Synthetic and Semisynthetic Opioids
276
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
276
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130


